Theoretically, ICI therapy can re-edit the tumor immune microenvironment to induce tumor regression, and the activity of PD-1/PD-L1 immune checkpoint inhibitors varies in different cancers, and many studies have demonstrated that they confer resistance in multiple cancer types. The gene discussed is CD274; the disease is cancer.